Literature DB >> 16170495

Prognostic factors for multiple sclerosis: the importance of natural history studies.

George C Ebers1.   

Abstract

Detailed studies of the natural history of untreated multiple sclerosis (MS) have been carried out in London, Ontario, Canada, over the past generation. There are now some 25,000 patient-years of follow-up in a cohort of slightly more than 1,000 individuals. From the data, it is clear that a number of factors are associated with long-term outcome of the disease. The Ontario database reveals several prognostic variables that are clinical in nature, which can be used to evaluate prognosis in any clinical subtype. The most important factors include the development of a progressive deficit and time to onset of progressive deficit. In addition, and independently, a high number of relapses in the first and second year is associated with poor long-term outcome, as is the development of early unremitting disability. An important question is whether or not primary-progressive (PP) MS represents an independent entity separate from secondary-progressive (SP) MS. No specific category of PP disease is distinguishable from SP disease using available clinical measures. There is reason to believe that magnetic resonance imaging (MRI) activity (when appropriately controlled for other unequally distributed factors, such as age) will be found to be very similar.

Entities:  

Mesh:

Year:  2005        PMID: 16170495     DOI: 10.1007/s00415-005-2012-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  27 in total

1.  CLINICAL STUDIES OF MULTIPLE SCLEROSIS IN ISRAEL. 3. CLINICAL COURSE AND PROGNOSIS RELATED TO AGE AT ONSET.

Authors:  U LEIBOWITZ; M ALTER; L HALPERN
Journal:  Neurology       Date:  1964-10       Impact factor: 9.910

Review 2.  Primary progressive multiple sclerosis.

Authors:  A J Thompson; C H Polman; D H Miller; W I McDonald; B Brochet; X Filippi M Montalban; J De Sá
Journal:  Brain       Date:  1997-06       Impact factor: 13.501

3.  The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course.

Authors:  B G Weinshenker; B Bass; G P Rice; J Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1989-12       Impact factor: 13.501

4.  Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis.

Authors:  F Fazekas; H Offenbacher; S Fuchs; R Schmidt; K Niederkorn; S Horner; H Lechner
Journal:  Neurology       Date:  1988-12       Impact factor: 9.910

5.  A clinical and laboratory study of benign multiple sclerosis.

Authors:  A J Thompson; M Hutchinson; J Brazil; C Feighery; E A Martin
Journal:  Q J Med       Date:  1986-01

6.  Sex distribution, age of onset and HLA profiles in two types of multiple sclerosis. A role for sex hormones and microbial infections in the development of autoimmunity?

Authors:  R Van Lambalgen; E A Sanders; J D'Amaro
Journal:  J Neurol Sci       Date:  1986-11       Impact factor: 3.181

7.  The natural history of multiple sclerosis: a geographically based study. 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis.

Authors:  D A Cottrell; M Kremenchutzky; G P Rice; W Hader; J Baskerville; G C Ebers
Journal:  Brain       Date:  1999-04       Impact factor: 13.501

8.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.

Authors:  F D Lublin; S C Reingold
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

9.  Major differences in the dynamics of primary and secondary progressive multiple sclerosis.

Authors:  A J Thompson; A G Kermode; D Wicks; D G MacManus; B E Kendall; D P Kingsley; W I McDonald
Journal:  Ann Neurol       Date:  1991-01       Impact factor: 10.422

10.  One year follow up study of primary and transitional progressive multiple sclerosis.

Authors:  V L Stevenson; D H Miller; S M Leary; M Rovaris; F Barkhof; B Brochet; V Dousset; M Filippi; R Hintzen; X Montalban; C H Polman; A Rovira; J de Sa; A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-06       Impact factor: 10.154

View more
  9 in total

Review 1.  Aggressive multiple sclerosis: proposed definition and treatment algorithm.

Authors:  Carolina A Rush; Heather J MacLean; Mark S Freedman
Journal:  Nat Rev Neurol       Date:  2015-06-02       Impact factor: 42.937

2.  Multiple sclerosis with a progressive course from onset in Lorraine-Eastern France.

Authors:  M Debouverie; S Louis; S Pittion-Vouyovitch; T Roederer; H Vespignani
Journal:  J Neurol       Date:  2007-06-25       Impact factor: 4.849

3.  Evidence for a two-stage disability progression in multiple sclerosis.

Authors:  Emmanuelle Leray; Jacqueline Yaouanq; Emmanuelle Le Page; Marc Coustans; David Laplaud; Joël Oger; Gilles Edan
Journal:  Brain       Date:  2010-04-27       Impact factor: 13.501

4.  Preserved decision making ability in early multiple sclerosis.

Authors:  S Simioni; C Ruffieux; J Kleeberg; L Bruggimann; J-M Annoni; M Schluep
Journal:  J Neurol       Date:  2008-11-13       Impact factor: 4.849

5.  Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score.

Authors:  Roberto Bergamaschi; Silvana Quaglini; Maria Trojano; Maria Pia Amato; Eleonora Tavazzi; Damiano Paolicelli; Valentina Zipoli; Alfredo Romani; Aurora Fuiani; Emilio Portaccio; Carlo Berzuini; Cristina Montomoli; Stefano Bastianello; Vittorio Cosi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-01-12       Impact factor: 10.154

6.  Estimating typical multiple sclerosis disability progression speed from clinical observations.

Authors:  Murray G Brown; Mark Asbridge; Vern Hicks; Sarah Kirby; Thomas J Murray; Pantelis Andreou; Dong Lin
Journal:  PLoS One       Date:  2014-10-17       Impact factor: 3.240

7.  Bioinformatics Analyses Determined the Distinct CNS and Peripheral Surrogate Biomarker Candidates Between Two Mouse Models for Progressive Multiple Sclerosis.

Authors:  Seiichi Omura; Fumitaka Sato; Nicholas E Martinez; Ah-Mee Park; Mitsugu Fujita; Nikki J Kennett; Urška Cvek; Alireza Minagar; J Steven Alexander; Ikuo Tsunoda
Journal:  Front Immunol       Date:  2019-03-19       Impact factor: 7.561

Review 8.  Combination of Probiotics and Natural Compounds to Treat Multiple Sclerosis via Warburg Effect.

Authors:  Anjali Kandiruthi Ravi; Saradhadevi Kuppusami Muthukrishnan
Journal:  Adv Pharm Bull       Date:  2021-09-29

9.  Native ancestry is associated with optic neuritis and age of onset in hispanics with multiple sclerosis.

Authors:  Lilyana Amezcua; Ashley H Beecham; Silvia R Delgado; Angel Chinea; Margaret Burnett; Clara Patricia Manrique; Refujia Gomez; Manuel Comabella; Xavier Montalban; Melissa Ortega; Leticia Tornes; Brett T Lund; Talat Islam; David Conti; Jorge R Oksenberg; Jacob L McCauley
Journal:  Ann Clin Transl Neurol       Date:  2018-09-23       Impact factor: 4.511

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.